<div class="container">

<table style="width: 100%;"><tr>
<td>PredP</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>The predictive probability criterion function for Phase II single-arm design</h2>

<h3>Description</h3>

<p>Lee and Liu's criterion function for determining the
trial decision cutoffs based on the predictive probability.
</p>


<h3>Usage</h3>

<pre><code class="language-R">PredP(x, n, nmax, a, b, p0, theta_t)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>x</code></td>
<td>
<p>the number of responses among <code class="reqn">n</code> patients treated by the experimental drug at a certain stage of the trial.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>n</code></td>
<td>
<p>the number of patients treated by the experimental drug at a certain stage of the trial.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nmax</code></td>
<td>
<p>the maximum number of patients treated by the experimental drug.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>a</code></td>
<td>
<p>the hyperparameter (shape1) of the Beta prior for the experimental drug.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>b</code></td>
<td>
<p>the hyperparameter (shape2) of the Beta prior for the experimental drug.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>p0</code></td>
<td>
<p>the the response rate for the standard drug.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta_t</code></td>
<td>
<p>the cutoff probability for efficacy including future patients; typically, <code class="reqn">\theta_T = [0.85, 0.95]</code>. Set 0.9 by default.</p>
</td>
</tr>
</table>
<h3>Value</h3>

<table><tr style="vertical-align: top;">
<td><code>prob</code></td>
<td>
<p>the predictive probability: <code class="reqn">PP = \sum\limits_{y=0}^{n_{max}-n} Pr(Y=y | x) I(\Pr(p &gt; p_0 | Y=y, x) \geq \theta_T) </code></p>
</td>
</tr></table>
<h3>References</h3>

<p>Lee, J. J., Liu, D. D. (2008).
A predictive probability design for phase II cancer clinical trials.
<em>Clinical Trials</em> <strong>5</strong>: 93-106.
</p>
<p>Yin, G. (2012).
<em>Clinical Trial Design: Bayesian and Frequentist Adaptive Methods.</em>
New York: Wiley.
</p>


<h3>Examples</h3>

<pre><code class="language-R"># Using vague prior Uniform(0,1), i.e. Beta(1,1)
PredP(16, 23, 40, 1, 1, 0.5, 0.9)
</code></pre>


</div>